ClinicalTrials.gg
CompletedNCT04018612Updated Mar 29, 2022Results posted

A Study of Acetaminophen for Post Surgical Dental Pain

A Phase 2 interventional study of Acetaminophen and Placebo in Pain, Postoperative and Dental Pain, sponsored by Nevakar, Inc.. Completed at 1 site in United States. Open to participants aged 17 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-03-29.

Sponsored by Nevakar, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
17 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 118 studies testing acetaminophen in Pain, Postoperative — 11 open to participants now, 13 under way, 1 of them phase 3. Acetaminophen · Pain, Postoperative.

Enrollment
47th of 118
110 · median 90
Started
2019
with 8 others
Phase 2
9 of 118
none open now
Registered
76th of 118
by date
Lead sponsor
3 of 118
Nevakar, Inc.

Among the 118 studies testing acetaminophen in Pain, Postoperative, this one is the 47th largest by enrollment, is one of 9 that started in 2019, is one of 9 in phase 2, and was the 76th registered.

Pain, Postoperative

5,654 studies on the registry are indexed under Pain, Postoperative; 1,233 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

11 of the 118 studies testing acetaminophen in Pain, Postoperative are open now, in 4 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About acetaminophen

Acetaminophen: first FDA approval 1968 (NEOPAP). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 676 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 327 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.

This study: 17 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 118 studies testing acetaminophen in Pain, Postoperative, or all of them as a file.
02

Study summary

To assess the safety, tolerability, analgesic, efficacy and pharmacokinetics of high dose acetaminophen relative to placebo and low dose acetaminophen relative to placebo over a 24 hour period in patient experiencing moderate to severe pain following the surgical removal of third molar.

Read the detailed description

This will be a randomized, double-blind, single-site, placebo-controlled, parallel-group study to assess similarities in safety, tolerability, efficacy, and pharmacokinetics of high dose acetaminophen given relative to placebo, and low dose acetaminophen given relative to placebo over a 24-hour period in patients experiencing moderate to severe postsurgical pain within 7 hours following surgical removal of 2 or more molars

03

Conditions studied

  • Pain, Postoperative
  • Dental Pain
04

Who can participate

Ages eligible
17 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients must be capable of reading, comprehending, and signing the /assent form;
  2. Male and female patients between 17-55 years of age;
  3. (BMI) ≤35.0 kg/m2
  4. Body weight of >50 kg
  5. Patients are American Society of Anaesthesiologists (ASA) Category I or II and are in good physical health as judged by a thorough history and physical examination;
  6. Patients without infections in the area of the impacted teeth;
  7. Patients must agree to refrain from ingesting any systemic or applying any topical analgesic medication for 3 days or 5 half-lives of the drug prior to and during the study;
  8. No alcohol for a minimum of 24 hours prior to the surgery;
  9. Female patients must be of non-child bearing potential, defined as for more than 1 year or surgically sterile (hysterectomy, tubal ligation/occlusion) or practicing an acceptable method of (hormonal oral, patch, or implant, double barrier method, intrauterine device, vasectomized or same sex partner, or abstinence). Patients using hormonal birth control must have been on a stable dose of treatment for at least 30 days and received at least 1 cycle of treatment prior to randomization. At Screening and at the day of surgery, all females of must have a negative (serum at screening and urine on day of surgery 1) pregnancy test and not be breastfeeding;
  10. Patients must have a negative urine drug screen for drugs of abuse at Screening and on the day of surgery. At the discretion of the Principal Investigator, a positive drug screen result may be permitted if the patient has been on a stable dose of an allowed medication for >30 days;
  11. Patients who are scheduled to undergo the surgical removal of up to 4 third molars of which at least two have to be mandibular molars with a difficulty rating of 4 or 5 and meeting the following criteria:

    • two full bony impactions
    • two partial bony impactions
    • one full bony impaction in combination with one partial bony impaction (see Appendix 1 for Impaction Difficulty Rating Scale);
  12. Patients able to comprehend and follow the requirements of the study (including availability on scheduled visit dates) based upon the research site's judgment.

Exclusion criteria

Exclusion Criteria:

  1. Patients with a history of any significant medical condition that, in the opinion of the Principal Investigator or his designee, would place the patient at increased risk such as: hepatic, renal, endocrine, cardiac, neurological, psychiatric, gastrointestinal, pulmonary, hematologic, or metabolic disorders, including glaucoma, diabetes, emphysema, and chronic bronchitis;
  2. Patients with a history of any type of within the past 5 years other than minor skin related cancers;
  3. Patients with a history of alcohol or substance abuse in the past three years according to Diagnostic and Statistical Manual (DSM) V and who do not satisfy Inclusion Criteria 10 (including a positive urine drug screen test);
  4. Patients with a known allergy or to any local anesthetic drug, acetaminophen, ibuprofen, or other NSAIDS;
  5. Patients who are taking any concomitant medications that might confound assessments of pain relief, such as psychotropic drugs, antidepressants, sedative hypnotics or any analgesics taken within three days or five times of their elimination half-lives, whichever is longer. Selective serotonin reuptake inhibitors (SSRIs) and selective noradrenaline reuptake inhibitors (SNRIs) are permitted if the patient has been on a stable dose for at least 30 days prior to screening;
  6. Patients who have smoked or chewed tobacco-containing substances within 48 hours prior to the day of surgery;
  7. Patients judged by the Principal Investigator to be unable or unwilling to comply with the requirements of the protocol;
  8. Patients who have used an drug within 30 days prior to the screening day or have previously participated in any Nevakar trial;
  9. Patients who have donated blood within 3 months prior to the screening day;
  10. Patients who are employees or relatives of employees of JBR Clinical Research or Nevakar, Inc.
  11. Patients with liver function tests (, AST) that are above the normal reference range.

    -

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
110 participants (actual)

Study arms

  • Active comparator
    High Dose Acetaminophen

    High Dose Acetaminophen Post Op

    Drug: Acetaminophen

  • Active comparator
    Low Dose Acetaminophen

    Low Dose Acetaminophen Post Op

    Drug: Acetaminophen

  • Placebo comparator
    Placebo

    Placebo Post Op

    Other: Placebo

Interventions

  • Acetaminophen is an analgesic and antipyretic

    Also known as: APAP

  • OtherPlacebo

    Saline

06

What researchers measure

Primary outcomes

  1. Sum of Pain Intensity Difference From 0 to 24 Hours (SPID24) Based on the 11 Point Numeric Pain Rating Scale

    Pain Intensity was self-reported over 24 hours, using a pain rating of 0-10 on the Numerical Rating Scale (NRS), with score between 0-10 (0= no pain; 10 = worst imaginable pain). Time weighted sum of pain intensity difference from 0 to 24 hours was reported. Pain Intensity (PI-NPRS) was collected at initiation of Dose 1 (T0) and post dose 0.5, 0.75, 1, 1.25, 1.75, 2.25 3.25, 4.25, 5.25, 6.25, 7.25, 8.25, 9.25, 10.25, 11.25, 12.25 (± 5 min) and 14.25, 16.25, 18.25, 20.25, 22.25, and 24.25 (± 10 min). SPID24 was include all nominal timepoints from T0 to T24.25 hours. SPID is calculated as Σ\[T(i) -T(i-1)\] x \[(PID(i-1) + PID(i))/2\], where T(0)=0, T(i) is the scheduled time, and PID(i) is the pain intensity difference (PID) score at time i. Pain intensity differences were calculated with respect to Baseline. A baseline assessment is defined as the last non-missing result prior to administration of the first dose of study medication.

    Time frame: Baseline (0.0) and 0.5, 0.75, 1, 1.25, 1.75, 2.25 3.25, 4.25, 5.25, 6.25, 7.25, 8.25, 9.25, 10.25, 11.25, 12.25 (± 5 min) and 14.25, 16.25, 18.25, 20.25, 22.25, and 24.25 (± 10 min) hours

  2. Sum of Pain Relief From 0 to 24 Hours (TOTPAR24) Based on a 5-point Likert Scale.

    Pain Relief Rating (PR) was scored on a 5-point scale (0=no-, 1=a little-, 2=some-, 3=a lot of-, and 4=complete- PR). PR was collected at initiation of Dose 1 (T0) and post dose 0.5, 0.75, 1, 1.25, 1.75, 2.25 3.25, 4.25, 5.25, 6.25, 7.25, 8.25, 9.25, 10.25, 11.25, 12.25 (± 5 min) and 14.25, 16.25, 18.25, 20.25, 22.25, and 24.25 (± 10 min) hours. TOTPAR24 is calculated as Sum (\[T(i) - T(i-1)\] x (PR(i-1) + PR(i)) / 2), where T(0)=0, T(i) is the actual time, and PR(i) is the pain relief score at time i. and calculated as Σ\[T(i) -T(i-1)\] x \[(PR(i-1) + PR(i))/2\], where T(0)=0, T(i) is the scheduled time, and PR(i) is the pain relief (PR) score at time i.

    Time frame: Baseline (0.0) and 0.5, 0.75, 1, 1.25, 1.75, 2.25 3.25, 4.25, 5.25, 6.25, 7.25, 8.25, 9.25, 10.25, 11.25, 12.25 (± 5 min) and 14.25, 16.25, 18.25, 20.25, 22.25, and 24.25 (± 10 min) hours

Secondary outcomes

  1. Time to Perceptible Pain Relief Confirmed (FPR-C) After Dose 1 Administration Stratified by Baseline Pain Score of Moderate or Severe for the 3 Treatment Groups

    Upon initiation of the infusion of Dose 1, the participants were given stopwatch #1 and asked to press the stopwatch when they first perceived any pain relief (first perceptible pain relief \[FPR\]) ; a record of the time was noted in the participant record. If a participant does not record perceptible pain relief and prematurely discontinued from the study prior to 24 hours, then the participant was censored at time of drop out. If a participant does not record perceptible pain relief prior to taking rescue medication, the participant was censored at 24 hours

    Time frame: 0 to 24 Hours

  2. Time to Meaningful Perceptible Relief (MPR) Measure Stratified by Baseline Pain Score of Moderate or Severe for the 3 Treatment Groups

    Upon initiation of the infusion of Dose 1, the participants were given a second stopwatch and asked to press the stopwatch if and when they feel any meaningful perceptible relief; a record of the time was noted in the participant record. If a participant does not record perceptible pain relief and was prematurely discontinued from the study prior to 24 hours, then the participant was censored at time of drop out. If a participant does not record perceptible pain relief prior to taking rescue medication, the participant was censored at 24 hours.

    Time frame: 0 to 24 Hours

  3. Patient Global Evaluation of the Study Medication

    Patients Global Evaluation was assessed on a scale of 0 (Poor), 1 (Fair), 2 (Good), 3 (Very Good) and 4 (Excellent) at 24.25 hours post-dose 1 or at participant withdrawal (if applicable), whichever occurred first. Least squares mean of the score are reported.

    Time frame: 0 to 24 Hours

  4. Pain Intensity Difference Rating (PID) at Different Timepoints After Dose 1 Administration

    Pain Intensity was self-reported over 24 hours, using a pain rating of 0-10 on the Numerical Rating Scale (NRS), with score between 0-10 (0= no pain; 10 = worst imaginable pain). Pain intensity differences were calculated with respect to Baseline at each time point after Dose 1 administration. A baseline assessment was defined as the last non-missing result prior to administration of the first dose of study medication

    Time frame: Baseline (0.0) and 0.5, 0.75, 1, 1.25, 1.75, 2.25 3.25, 4.25, 5.25, 6.25, 7.25, 8.25, 9.25, 10.25, 11.25, 12.25 (± 5 min) and 14.25, 16.25, 18.25, 20.25, 22.25, and 24.25 hours (± 10 min)

  5. Pain Intensity Rating at Different Timepoints After Dose 1 Administration

    Pain intensity is reported using the 11-point Numerical Rating Scale (NRS), with score between 0-10 (0= no pain; 10 = worst imaginable pain).

    Time frame: 0 to 24 hours

  6. Pain Relief (PR) Ratings at Each Observation Time After Dose 1 Administration

    Pain Relief is reported on a 5-Point Categorical Pain Relief Assessment scale: 0 = No Pain Relief, 1 = A Little Pain Relief, 2 = Some Pain Relief, 3 = A Lot of Pain Relief, 4 = Complete Pain Relief.

    Time frame: 0 to 24 hours

  7. Time to Treatment Failure

    Time to treatment failure is defined as time to first dose of rescue medication after Dose 1 or withdrawal from the study for any reason. If a participant does not take rescue medication or withdraw from the study prior to 24 hours, the participant was censored at 24 hours

    Time frame: 0 to 24 Hours

Other outcomes

  1. Mean Change From Baseline to 24 Hours in Vital Signs (Systolic Blood Pressure)

    Change from Baseline in systolic blood pressure is the value at 24 hours minus value at Baseline. Baseline was defined as the last non-missing result prior to administration of the first dose of study drug. Systolic blood pressure is obtained at screening, prior to surgery and at Hours 4, 8, 12, 16, 20 and 24 following initiation of dose (±10 min).

    Time frame: 0 to 24 hours

  2. Mean Change From Baseline to 24 Hours in Vital Signs (Diastolic Blood Pressure)

    Change from Baseline in diastolic blood pressure is the value at 24 hours minus value at Baseline. Baseline was defined as the last non-missing result prior to administration of the first dose of study drug. Diastolic blood pressure is obtained at screening, prior to surgery and at Hours 4, 8, 12, 16, 20 and 24 following initiation of dose (±10 min)

    Time frame: 0 to 24 hours

  3. Mean Change From Baseline to 24 Hours in Vital Signs (Temperature)

    Change from Baseline in temperature is the value at 24 hours minus value at Baseline. Baseline was defined as the last non-missing result prior to administration of the first dose of study drug. Temperature is obtained at screening, prior to surgery and at Hours 4, 8, 12, 16, 20 and 24 following initiation of dose (±10 min)

    Time frame: 0 to 24 hours

  4. Mean Change From Baseline to 24 Hours in Vital Signs (Pulse Rate)

    Change from Baseline in pulse rate is the value at 24 hours minus value at Baseline. Baseline was defined as the last non-missing result prior to administration of the first dose of study drug. Pulse rate is obtained at screening, prior to surgery and at Hours 4, 8, 12, 16, 20 and 24 following initiation of dose (±10 min)

    Time frame: 0 to 24 hours

  5. Mean Change From Baseline to 24 Hours in Vital Signs (Respiratory Rate)

    Change from Baseline in respiratory rate was the value at 24 hours minus value at Baseline. Baseline was defined as the last non-missing result prior to administration of the first dose of study drug. Respiratory rate was obtained at screening, prior to surgery and at Hours 4, 8, 12, 16, 20 and 24 following initiation of dose (±10 min)

    Time frame: 0 to 24 hours

  6. Area Under the Plasma Concentration-Time Curve From Time of Administration to 24 Hours After Dosing (AUC 0-24h)

    The Area Under the Plasma Concentration-Time Curve (AUC) is a measure of the plasma concentration of the drug over time. It is used to characterize drug absorption. The values for pharmacokinetic (PK) evaluable population-excluding participants with positive pre-dose concentrations have been populated. The samples were collected at 5 min prior to Dose 1, and at 0.25, 0.5, 0.75, 1.0, 2.0, 4.0, 6.25, 8.0, 8.25, 8.25, 12.0, 12.25, 16.0, 16.25, 18.0, 18.25, 24.25 hours post-dose 1.

    Time frame: Pre-dose, and 0.25, 0.5, 0.75, 1.0, 2.0, 4.0, 6.25, 8.0, 8.25, 8.25, 12.0, 12.25, 16.0, 16.25, 18.0, 18.25, 24.25 hours post-dose

  7. Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC[0-infinity])

    The AUC(0-infinity) is area under the plasma concentration-time curve from time zero to infinite time. The samples were collected at 5 min prior to Dose 1, and at 0.25, 0.5, 0.75, 1.0, 2.0, 4.0, 6.25, 8.0, 8.25, 8.25, 12.0, 12.25, 16.0, 16.25, 18.0, 18.25, 24.25 hours post-dose 1.

    Time frame: Pre-dose, and 0.25, 0.5, 0.75, 1.0, 2.0, 4.0, 6.25, 8.0, 8.25, 8.25, 12.0, 12.25, 16.0, 16.25, 18.0, 18.25, 24.25 hours post-dose

  8. Half-life

    The half-life (t 1/2) is the time measured for the plasma concentration to decrease by 1 half to its original concentration.

    Time frame: Pre-dose, and 0.25, 0.5, 0.75, 1.0, 2.0, 4.0, 6.25, 8.0, 8.25, 8.25, 12.0, 12.25, 16.0, 16.25, 18.0, 18.25, 24.25 hours post-dose

  9. Maximum Observed Plasma Concentration (Cmax)

    The Plasma Concentration (Cmax) is defined as maximum observed concentration

    Time frame: Pre-dose, and 0.25, 0.5, 0.75, 1.0, 2.0, 4.0, 6.25, 8.0, 8.25, 8.25, 12.0, 12.25, 16.0, 16.25, 18.0, 18.25, 24.25 hours post-dose

07

Results

Posted Mar 29, 2022

Participant flow

Participants were recruited from April 2019 till July 2019 from the site

Participant flow — Overall Study
MilestoneHigh Dose APAPLow Dose APAPPlacebo
Started444422
Completed434421
Not completed101
Withdrew: Withdrawal by subject101

Outcome measures

PrimarySum of Pain Intensity Difference From 0 to 24 Hours (SPID24) Based on the 11 Point Numeric Pain Rating Scale

Pain Intensity was self-reported over 24 hours, using a pain rating of 0-10 on the Numerical Rating Scale (NRS), with score between 0-10 (0= no pain; 10 = worst imaginable pain). Time weighted sum of pain intensity difference from 0 to 24 hours was reported. Pain Intensity (PI-NPRS) was collected at initiation of Dose 1 (T0) and post dose 0.5, 0.75, 1, 1.25, 1.75, 2.25 3.25, 4.25, 5.25, 6.25, 7.25, 8.25, 9.25, 10.25, 11.25, 12.25 (± 5 min) and 14.25, 16.25, 18.25, 20.25, 22.25, and 24.25 (± 10 min). SPID24 was include all nominal timepoints from T0 to T24.25 hours. SPID is calculated as Σ\[T(i) -T(i-1)\] x \[(PID(i-1) + PID(i))/2\], where T(0)=0, T(i) is the scheduled time, and PID(i) is the pain intensity difference (PID) score at time i. Pain intensity differences were calculated with respect to Baseline. A baseline assessment is defined as the last non-missing result prior to administration of the first dose of study medication.

Time frame:
Baseline (0.0) and 0.5, 0.75, 1, 1.25, 1.75, 2.25 3.25, 4.25, 5.25, 6.25, 7.25, 8.25, 9.25, 10.25, 11.25, 12.25 (± 5 min) and 14.25, 16.25, 18.25, 20.25, 22.25, and 24.25 (± 10 min) hours
Reported as:
Least squares mean · score on a scale
Sum of Pain Intensity Difference From 0 to 24 Hours (SPID24) Based on the 11 Point Numeric Pain Rating Scale
score on a scaleHigh Dose APAPLow Dose APAPPlacebo
Sum of Pain Intensity Difference From 0 to 24 Hours (SPID24) Based on the 11 Point Numeric Pain Rating Scale-96.80 ± 6.369-100.69 ± 6.333-74.96 ± 9.055
Statistical analysis
  • High Dose APAP vs Placebo · ANCOVA · p = 0.0258 · Ls mean difference: -21.84SPID24 was analyzed using ANCOVA model with treatment group as a fixed effect and baseline (BL) Pain Intensity-Numerical Pain Relief Scale (PI-NPRS) as a covariate. The lower limit of one-sided 90% confidence interval (CI) was -∞
  • Low Dose APAP vs Placebo · ANCOVA · p = 0.0115 · Ls mean difference: -25.74SPID24 was analyzed using an analysis of covariance (ANCOVA) model with treatment group as a fixed effect and baseline PI-NPRS as a covariate. The lower limit of one-sided 90% CI was -∞
PrimarySum of Pain Relief From 0 to 24 Hours (TOTPAR24) Based on a 5-point Likert Scale.

Pain Relief Rating (PR) was scored on a 5-point scale (0=no-, 1=a little-, 2=some-, 3=a lot of-, and 4=complete- PR). PR was collected at initiation of Dose 1 (T0) and post dose 0.5, 0.75, 1, 1.25, 1.75, 2.25 3.25, 4.25, 5.25, 6.25, 7.25, 8.25, 9.25, 10.25, 11.25, 12.25 (± 5 min) and 14.25, 16.25, 18.25, 20.25, 22.25, and 24.25 (± 10 min) hours. TOTPAR24 is calculated as Sum (\[T(i) - T(i-1)\] x (PR(i-1) + PR(i)) / 2), where T(0)=0, T(i) is the actual time, and PR(i) is the pain relief score at time i. and calculated as Σ\[T(i) -T(i-1)\] x \[(PR(i-1) + PR(i))/2\], where T(0)=0, T(i) is the scheduled time, and PR(i) is the pain relief (PR) score at time i.

Time frame:
Baseline (0.0) and 0.5, 0.75, 1, 1.25, 1.75, 2.25 3.25, 4.25, 5.25, 6.25, 7.25, 8.25, 9.25, 10.25, 11.25, 12.25 (± 5 min) and 14.25, 16.25, 18.25, 20.25, 22.25, and 24.25 (± 10 min) hours
Reported as:
Mean · score on a scale
Sum of Pain Relief From 0 to 24 Hours (TOTPAR24) Based on a 5-point Likert Scale.
score on a scaleHigh Dose APAPLow Dose APAPPlacebo
Sum of Pain Relief From 0 to 24 Hours (TOTPAR24) Based on a 5-point Likert Scale.55.82 ± 3.02455.24 ± 3.00743.11 ± 4.300
Statistical analysis
  • High Dose APAP vs Placebo · ANCOVA · p = 0.0087 · Ls mean difference: 12.72TOTPAR24 was analyzed using an ANCOVA model with treatment group as a fixed effect and baseline PI-NPRS as a covariate. The upper limit of one-sided 90% CI was +∞
  • Low Dose APAP vs Placebo · ANCOVA · p = 0.0120 · Ls mean difference: 12.14TOTPAR24 was analyzed using an ANCOVA model with treatment group as a fixed effect and baseline PI-NPRS as a covariate. The upper limit of one-sided 90% CI was +∞
SecondaryTime to Perceptible Pain Relief Confirmed (FPR-C) After Dose 1 Administration Stratified by Baseline Pain Score of Moderate or Severe for the 3 Treatment Groups

Upon initiation of the infusion of Dose 1, the participants were given stopwatch #1 and asked to press the stopwatch when they first perceived any pain relief (first perceptible pain relief \[FPR\]) ; a record of the time was noted in the participant record. If a participant does not record perceptible pain relief and prematurely discontinued from the study prior to 24 hours, then the participant was censored at time of drop out. If a participant does not record perceptible pain relief prior to taking rescue medication, the participant was censored at 24 hours

Time frame:
0 to 24 Hours
Reported as:
Median · hours
Time to Perceptible Pain Relief Confirmed (FPR-C) After Dose 1 Administration Stratified by Baseline Pain Score of Moderate or Severe for the 3 Treatment Groups
hoursHigh Dose APAPLow Dose APAPPlacebo
Median time to FPR-C (hours)- for moderate baseline categorical pain intensity score0.215 (0.080 to 1.000)0.160 (0.030 to 0.430)0.595 (0.060 to 24.00)
Median time to FPR-C (hours)- for severe baseline categorical pain intensity score0.160 (0.030 to 24.00)0.220 (0.060 to 24.00)0.890 (0.040 to 24.00)
SecondaryTime to Meaningful Perceptible Relief (MPR) Measure Stratified by Baseline Pain Score of Moderate or Severe for the 3 Treatment Groups

Upon initiation of the infusion of Dose 1, the participants were given a second stopwatch and asked to press the stopwatch if and when they feel any meaningful perceptible relief; a record of the time was noted in the participant record. If a participant does not record perceptible pain relief and was prematurely discontinued from the study prior to 24 hours, then the participant was censored at time of drop out. If a participant does not record perceptible pain relief prior to taking rescue medication, the participant was censored at 24 hours.

Time frame:
0 to 24 Hours
Reported as:
Median · hours
Time to Meaningful Perceptible Relief (MPR) Measure Stratified by Baseline Pain Score of Moderate or Severe for the 3 Treatment Groups
hoursHigh Dose APAPLow Dose APAPPlacebo
Median time to MPR (hours)- for moderate baseline categorical pain intensity score0.660 (0.250 to 24.00)0.310 (0.110 to 24.00)NA (NA to NA)
Median time to MPR (hours)- for severe baseline categorical pain intensity score0.680 (0.120 to 24.00)0.870 (0.150 to 24.00)NA (NA to NA)
SecondaryPatient Global Evaluation of the Study Medication

Patients Global Evaluation was assessed on a scale of 0 (Poor), 1 (Fair), 2 (Good), 3 (Very Good) and 4 (Excellent) at 24.25 hours post-dose 1 or at participant withdrawal (if applicable), whichever occurred first. Least squares mean of the score are reported.

Time frame:
0 to 24 Hours
Reported as:
Least squares mean · score on a scale
Patient Global Evaluation of the Study Medication
score on a scaleHigh Dose APAPLow Dose APAPPlacebo
Patient Global Evaluation of the Study Medication2.8 ± 0.162.7 ± 0.152.3 ± 0.22
SecondaryPain Intensity Difference Rating (PID) at Different Timepoints After Dose 1 Administration

Pain Intensity was self-reported over 24 hours, using a pain rating of 0-10 on the Numerical Rating Scale (NRS), with score between 0-10 (0= no pain; 10 = worst imaginable pain). Pain intensity differences were calculated with respect to Baseline at each time point after Dose 1 administration. A baseline assessment was defined as the last non-missing result prior to administration of the first dose of study medication

Time frame:
Baseline (0.0) and 0.5, 0.75, 1, 1.25, 1.75, 2.25 3.25, 4.25, 5.25, 6.25, 7.25, 8.25, 9.25, 10.25, 11.25, 12.25 (± 5 min) and 14.25, 16.25, 18.25, 20.25, 22.25, and 24.25 hours (± 10 min)
Reported as:
Mean · score on a scale
Pain Intensity Difference Rating (PID) at Different Timepoints After Dose 1 Administration
score on a scaleHigh Dose APAPLow Dose APAPPlacebo
0.5-2.5 ± 1.65-3.1 ± 2.01-0.7 ± 1.28
0.75-3.3 ± 1.88-3.5 ± 2.10-0.8 ± 1.40
1-3.7 ± 1.89-3.8 ± 2.12-0.8 ± 1.44
1.25-3.9 ± 2.02-4.0 ± 2.29-0.7 ± 1.52
1.75-3.9 ± 1.97-3.7 ± 2.45-0.7 ± 1.59
2.25-3.8 ± 2.16-3.6 ± 2.44-0.7 ± 1.67
3.25-3.4 ± 2.32-3.0 ± 2.39-0.9 ± 1.95
4.25-3.4 ± 2.40-2.9 ± 2.32-0.9 ± 1.97
5.25-3.3 ± 2.48-2.8 ± 2.39-2.4 ± 2.59
6.25-3.2 ± 2.48-3.5 ± 2.49-3.7 ± 2.32
7.25-3.0 ± 2.61-4.1 ± 2.34-4.2 ± 1.99
8.25-3.8 ± 2.72-4.4 ± 2.29-3.7 ± 2.36
9.25-4.5 ± 2.89-4.7 ± 2.18-3.6 ± 2.26
10.25-4.6 ± 2.71-5.0 ± 1.98-3.4 ± 2.22
11.25-4.7 ± 2.44-4.5 ± 1.99-3.3 ± 2.28
12.25-4.9 ± 1.85-4.5 ± 2.31-2.7 ± 2.27
14.25-3.7 ± 2.13-5.0 ± 2.42-2.9 ± 1.97
16.25-3.5 ± 2.29-4.4 ± 2.08-2.9 ± 1.97
18.25-4.4 ± 2.34-4.5 ± 2.27-3.5 ± 1.97
20.25-4.7 ± 2.04-4.9 ± 2.37-3.6 ± 2.24
22.25-4.7 ± 2.25-5.0 ± 2.35-3.9 ± 2.19
24.25-4.6 ± 2.29-5.1 ± 2.42-4.3 ± 1.86
SecondaryPain Intensity Rating at Different Timepoints After Dose 1 Administration

Pain intensity is reported using the 11-point Numerical Rating Scale (NRS), with score between 0-10 (0= no pain; 10 = worst imaginable pain).

Time frame:
0 to 24 hours
Reported as:
Mean · score on a scale
Pain Intensity Rating at Different Timepoints After Dose 1 Administration
score on a scaleHigh Dose APAPLow Dose APAPPlacebo
0.54.8 ± 1.834.4 ± 1.976.1 ± 1.42
0.754.0 ± 2.124.0 ± 1.986.0 ± 1.70
13.6 ± 1.983.7 ± 2.016.0 ± 1.68
1.253.4 ± 2.163.5 ± 2.146.2 ± 1.89
1.753.5 ± 2.243.8 ± 2.336.2 ± 1.94
2.253.6 ± 2.403.9 ± 2.396.2 ± 1.97
3.253.9 ± 2.534.5 ± 2.486.0 ± 2.17
4.254.0 ± 2.584.6 ± 2.336.0 ± 2.21
5.254.0 ± 2.484.7 ± 2.444.5 ± 2.56
6.254.2 ± 2.524.0 ± 2.593.2 ± 2.11
7.254.3 ± 2.463.4 ± 2.222.7 ± 1.86
8.253.5 ± 2.583.1 ± 2.203.2 ± 2.30
9.252.9 ± 2.712.8 ± 1.953.3 ± 2.25
10.252.8 ± 2.482.5 ± 1.683.5 ± 2.15
11.252.7 ± 2.273.0 ± 1.663.5 ± 2.24
12.252.5 ± 1.833.0 ± 2.094.1 ± 2.32
14.253.6 ± 2.292.5 ± 2.114.0 ± 2.08
16.253.8 ± 2.553.1 ± 2.014.0 ± 2.21
18.252.9 ± 2.583.0 ± 2.233.4 ± 1.99
20.252.7 ± 2.282.6 ± 2.143.2 ± 2.22
22.252.6 ± 2.582.5 ± 1.963.0 ± 2.16
24.252.8 ± 2.382.4 ± 2.062.61 ± 1.71
SecondaryPain Relief (PR) Ratings at Each Observation Time After Dose 1 Administration

Pain Relief is reported on a 5-Point Categorical Pain Relief Assessment scale: 0 = No Pain Relief, 1 = A Little Pain Relief, 2 = Some Pain Relief, 3 = A Lot of Pain Relief, 4 = Complete Pain Relief.

Time frame:
0 to 24 hours
Reported as:
Mean · score on a scale
Pain Relief (PR) Ratings at Each Observation Time After Dose 1 Administration
score on a scaleHigh Dose APAPLow Dose APAPPlacebo
0.51.7 ± 0.951.8 ± 0.940.6 ± 0.85
0.752.0 ± 1.022.0 ± 0.980.6 ± 0.85
12.1 ± 0.932.2 ± 0.960.6 ± 0.85
1.252.3 ± 0.972.2 ± 0.990.6 ± 0.85
1.752.3 ± 0.972.0 ± 1.070.6 ± 0.90
2.252.2 ± 1.092.0 ± 1.050.6 ± 0.90
3.252.0 ± 1.181.7 ± 1.120.8 ± 1.15
4.252.0 ± 1.211.6 ± 1.120.7 ± 1.08
5.251.9 ± 1.201.5 ± 1.211.5 ± 1.44
6.251.9 ± 1.231.9 ± 1.152.1 ± 1.25
7.251.8 ± 1.212.2 ± 1.032.5 ± 1.10
8.252.2 ± 1.152.4 ± 1.062.2 ± 1.27
9.252.6 ± 1.222.5 ± 0.932.1 ± 1.19
10.252.6 ± 1.102.7 ± 0.802.0 ± 1.20
11.252.7 ± 0.972.5 ± 0.872.0 ± 1.31
12.252.7 ± 0.832.4 ± 1.041.6 ± 1.33
14.252.1 ± 1.002.6 ± 1.041.8 ± 1.11
16.252.1 ± 1.142.3 ± 1.061.8 ± 1.14
18.252.5 ± 1.102.4 ± 1.022.1 ± 1.17
20.252.7 ± 1.002.6 ± 0.952.2 ± 1.18
22.252.7 ± 1.112.6 ± 0.942.3 ± 1.09
24.252.5 ± 1.122.7 ± 0.992.5 ± 0.91
SecondaryTime to Treatment Failure

Time to treatment failure is defined as time to first dose of rescue medication after Dose 1 or withdrawal from the study for any reason. If a participant does not take rescue medication or withdraw from the study prior to 24 hours, the participant was censored at 24 hours

Time frame:
0 to 24 Hours
Reported as:
Median · hours
Time to Treatment Failure
hoursHigh Dose APAPLow Dose APAPPlacebo
Median time to treatment failure- for moderate baseline categorical pain intensity scoreNA (NA to NA)NA (NA to NA)3.680 (1.100 to 24.00)
Median time to treatment failure for severe baseline categorical pain intensity scoreNA (NA to NA)NA (NA to NA)1.335 (1.030 to 24.00)
Other pre-specifiedMean Change From Baseline to 24 Hours in Vital Signs (Systolic Blood Pressure)

Change from Baseline in systolic blood pressure is the value at 24 hours minus value at Baseline. Baseline was defined as the last non-missing result prior to administration of the first dose of study drug. Systolic blood pressure is obtained at screening, prior to surgery and at Hours 4, 8, 12, 16, 20 and 24 following initiation of dose (±10 min).

Time frame:
0 to 24 hours
Reported as:
Mean · mm Hg
Mean Change From Baseline to 24 Hours in Vital Signs (Systolic Blood Pressure)
mm HgHigh Dose APAPLow Dose APAPPlacebo
Mean Change From Baseline to 24 Hours in Vital Signs (Systolic Blood Pressure)1.6 ± 10.781.0 ± 11.399.2 ± 10.99
Other pre-specifiedMean Change From Baseline to 24 Hours in Vital Signs (Diastolic Blood Pressure)

Change from Baseline in diastolic blood pressure is the value at 24 hours minus value at Baseline. Baseline was defined as the last non-missing result prior to administration of the first dose of study drug. Diastolic blood pressure is obtained at screening, prior to surgery and at Hours 4, 8, 12, 16, 20 and 24 following initiation of dose (±10 min)

Time frame:
0 to 24 hours
Reported as:
Mean · mm Hg
Mean Change From Baseline to 24 Hours in Vital Signs (Diastolic Blood Pressure)
mm HgHigh Dose APAPLow Dose APAPPlacebo
Mean Change From Baseline to 24 Hours in Vital Signs (Diastolic Blood Pressure)-0.2 ± 8.822.3 ± 9.565.2 ± 11.08
Other pre-specifiedMean Change From Baseline to 24 Hours in Vital Signs (Temperature)

Change from Baseline in temperature is the value at 24 hours minus value at Baseline. Baseline was defined as the last non-missing result prior to administration of the first dose of study drug. Temperature is obtained at screening, prior to surgery and at Hours 4, 8, 12, 16, 20 and 24 following initiation of dose (±10 min)

Time frame:
0 to 24 hours
Reported as:
Mean · degrees Celsius
Mean Change From Baseline to 24 Hours in Vital Signs (Temperature)
degrees CelsiusHigh Dose APAPLow Dose APAPPlacebo
Mean Change From Baseline to 24 Hours in Vital Signs (Temperature)0.12 ± 0.3360.21 ± 0.2750.06 ± 0.347
Other pre-specifiedMean Change From Baseline to 24 Hours in Vital Signs (Pulse Rate)

Change from Baseline in pulse rate is the value at 24 hours minus value at Baseline. Baseline was defined as the last non-missing result prior to administration of the first dose of study drug. Pulse rate is obtained at screening, prior to surgery and at Hours 4, 8, 12, 16, 20 and 24 following initiation of dose (±10 min)

Time frame:
0 to 24 hours
Reported as:
Mean · beats/minute
Mean Change From Baseline to 24 Hours in Vital Signs (Pulse Rate)
beats/minuteHigh Dose APAPLow Dose APAPPlacebo
Mean Change From Baseline to 24 Hours in Vital Signs (Pulse Rate)5.0 ± 11.854.2 ± 11.585.7 ± 11.17
Other pre-specifiedMean Change From Baseline to 24 Hours in Vital Signs (Respiratory Rate)

Change from Baseline in respiratory rate was the value at 24 hours minus value at Baseline. Baseline was defined as the last non-missing result prior to administration of the first dose of study drug. Respiratory rate was obtained at screening, prior to surgery and at Hours 4, 8, 12, 16, 20 and 24 following initiation of dose (±10 min)

Time frame:
0 to 24 hours
Reported as:
Mean · breaths/minute
Mean Change From Baseline to 24 Hours in Vital Signs (Respiratory Rate)
breaths/minuteHigh Dose APAPLow Dose APAPPlacebo
Mean Change From Baseline to 24 Hours in Vital Signs (Respiratory Rate)0.3 ± 3.39-0.6 ± 4.12-1.3 ± 3.68
Other pre-specifiedArea Under the Plasma Concentration-Time Curve From Time of Administration to 24 Hours After Dosing (AUC 0-24h)

The Area Under the Plasma Concentration-Time Curve (AUC) is a measure of the plasma concentration of the drug over time. It is used to characterize drug absorption. The values for pharmacokinetic (PK) evaluable population-excluding participants with positive pre-dose concentrations have been populated. The samples were collected at 5 min prior to Dose 1, and at 0.25, 0.5, 0.75, 1.0, 2.0, 4.0, 6.25, 8.0, 8.25, 8.25, 12.0, 12.25, 16.0, 16.25, 18.0, 18.25, 24.25 hours post-dose 1.

Time frame:
Pre-dose, and 0.25, 0.5, 0.75, 1.0, 2.0, 4.0, 6.25, 8.0, 8.25, 8.25, 12.0, 12.25, 16.0, 16.25, 18.0, 18.25, 24.25 hours post-dose
Reported as:
Least squares mean · microgram*hour/milliliter
Area Under the Plasma Concentration-Time Curve From Time of Administration to 24 Hours After Dosing (AUC 0-24h)
microgram*hour/milliliterHigh Dose APAPLow Dose APAP
Area Under the Plasma Concentration-Time Curve From Time of Administration to 24 Hours After Dosing (AUC 0-24h)236326.3081 ± 1.06026231104.0073 ± 1.05427
Other pre-specifiedArea Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC[0-infinity])

The AUC(0-infinity) is area under the plasma concentration-time curve from time zero to infinite time. The samples were collected at 5 min prior to Dose 1, and at 0.25, 0.5, 0.75, 1.0, 2.0, 4.0, 6.25, 8.0, 8.25, 8.25, 12.0, 12.25, 16.0, 16.25, 18.0, 18.25, 24.25 hours post-dose 1.

Time frame:
Pre-dose, and 0.25, 0.5, 0.75, 1.0, 2.0, 4.0, 6.25, 8.0, 8.25, 8.25, 12.0, 12.25, 16.0, 16.25, 18.0, 18.25, 24.25 hours post-dose
Reported as:
Geometric mean · hour*nanogram per milliliter
Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC[0-infinity])
hour*nanogram per milliliterHigh Dose APAPLow Dose APAP
Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC[0-infinity])75925.2553 ± 22.40555018.1382 ± 27.089
Other pre-specifiedHalf-life

The half-life (t 1/2) is the time measured for the plasma concentration to decrease by 1 half to its original concentration.

Time frame:
Pre-dose, and 0.25, 0.5, 0.75, 1.0, 2.0, 4.0, 6.25, 8.0, 8.25, 8.25, 12.0, 12.25, 16.0, 16.25, 18.0, 18.25, 24.25 hours post-dose
Reported as:
Mean · hours
Half-life
hoursHigh Dose APAPLow Dose APAP
Half-life2.565 ± 0.57742.360 ± 0.4134
Other pre-specifiedMaximum Observed Plasma Concentration (Cmax)

The Plasma Concentration (Cmax) is defined as maximum observed concentration

Time frame:
Pre-dose, and 0.25, 0.5, 0.75, 1.0, 2.0, 4.0, 6.25, 8.0, 8.25, 8.25, 12.0, 12.25, 16.0, 16.25, 18.0, 18.25, 24.25 hours post-dose
Reported as:
Geometric mean · nanogram per milliliter (ng/ml)
Maximum Observed Plasma Concentration (Cmax)
nanogram per milliliter (ng/ml)High Dose APAPLow Dose APAP
Maximum Observed Plasma Concentration (Cmax)39531.4 ± 2628495.6 ± 30

Adverse events

Collected over Up to 7 days (± 2 days). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
High Dose APAP0/44 (0%)0/44 (0%)9/44 (20.5%)
Low Dose APAP0/44 (0%)0/44 (0%)13/44 (29.5%)
Placebo0/22 (0%)0/22 (0%)7/22 (31.8%)
Most frequent other events
Showing 10 of 13
Most frequent other events
EventHigh Dose APAPLow Dose APAPPlacebo
HyperbilirubinaemiaHepatobiliary disorders7/448/446/22
NauseaGastrointestinal disorders1/441/441/22
DizzinessNervous system disorders0/440/441/22
HeadacheNervous system disorders0/440/441/22
TachycardiaCardiac disorders0/441/440/22
Hypoaesthesia oralGastrointestinal disorders0/441/440/22
Infusion site extravasationGeneral disorders1/440/440/22
Infusion site haematomaGeneral disorders1/440/440/22
PyrexiaGeneral disorders1/441/440/22
Postoperative wound infectionInfections and infestations0/441/440/22

Baseline characteristics

Baseline analysis population was the Safety Population that included all randomized participants who received the study medication.

Age, Continuous
Age, Continuous(years)High Dose APAPLow Dose APAPPlaceboTotal
Mean18.7 ± 2.0618.8 ± 2.3119.3 ± 2.4218.9 ± 2.23
Sex: Female, Male
Sex: Female, Male(Participants)High Dose APAPLow Dose APAPPlaceboTotal
Female25221158
Male19221152
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)High Dose APAPLow Dose APAPPlaceboTotal
Race-Asian1001
Race-White393922100
Race-Others2406
Race-Black or African American1001
Race- Native Hawaiian or Other Pacific Islander1102
Ethnicity-Hispanic or Latino98118
Ethinicity-Not Hispanic or Latino35362192
Body Mass Index
Body Mass Index(kg/m^2)High Dose APAPLow Dose APAPPlaceboTotal
Mean24.45 ± 4.12424.33 ± 3.76225.49 ± 4.86924.61 ± 4.130
Categorical pain intensity score
Categorical pain intensity score(Participants)High Dose APAPLow Dose APAPPlaceboTotal
None (0)0000
Mild (1)0000
Moderate (2)14111035
Severe (3)30331275
NRS pain intensity
NRS pain intensity(Participants)High Dose APAPLow Dose APAPPlaceboTotal
0 = No pain0000
10000
20000
30000
40000
51113
6117826
71312631
81318738
93508
10 = Worst imaginable pain3104
08

Study locations

1 site
  • JBR
    Salt Lake City, Utah 84107, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2019 to primary completion in Jul 2019, 3 months.

Results were first posted in Mar 2022, 2 years 8 months after primary completion.

Of 49 industry-sponsored phase 2 interventional studies under Pain, Postoperative, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 11. This study's 3 months is below that.

Counting every sponsor, half of 139 studies reached it within 12 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2019
First posted
Jul 12, 2019
StartActual
Apr 25, 2019
Primary completionActual
Jul 26, 2019
CompletionActual
Aug 15, 2019
Results first posted
Mar 29, 2022
Last update
Mar 29, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 29, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04018612
Lead sponsor
Nevakar, Inc.
Responsible party
Sponsor
First posted
Jul 12, 2019
Start date
Apr 25, 2019
Primary completion
Jul 26, 2019
Completion
Aug 15, 2019
Results posted
Mar 29, 2022
Last update
Mar 29, 2022

Study contacts

Eric Lang, MD
study director · Nevakar, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acetaminophen

Start the discussion